PDCD1 and neoplasm: Moreover, whereas BayK8644 reinforced the antitumor effects of anti-PD-1 treatment in mouse melanoma, it did not enhance tumor growth inhibition induced by anti-CTLA-4 and anti-PD-1 combination therapy, at least in this model (Figure S8O).